Product information and disease descriptionProduct descriptionProduct information
Dosing and administration
6 evidence topics · 8 sources
Dersimelagon (MT-7117)
Erythropoietic protoporphyria or X-linked protoporphyria
- Manufacturer
- LEO Pharma
- Regulatory submission
- NDA submitted June 2026
- Launch
- Potential launch in 2027
- Last updated